179 related articles for article (PubMed ID: 9034152)
1. Mapping the active site of CD59.
Yu J; Abagyan R; Dong S; Gilbert A; Nussenzweig V; Tomlinson S
J Exp Med; 1997 Feb; 185(4):745-53. PubMed ID: 9034152
[TBL] [Abstract][Full Text] [Related]
2. Activity after site-directed mutagenesis of CD59 on complement-mediated cytolysis.
Zhu X; Gao M; Ren S; Wang Q; Lin C
Cell Mol Immunol; 2008 Apr; 5(2):141-6. PubMed ID: 18445344
[TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59.
Bodian DL; Davis SJ; Morgan BP; Rushmere NK
J Exp Med; 1997 Feb; 185(3):507-16. PubMed ID: 9053451
[TBL] [Abstract][Full Text] [Related]
4. Mapping the intermedilysin-human CD59 receptor interface reveals a deep correspondence with the binding site on CD59 for complement binding proteins C8alpha and C9.
Wickham SE; Hotze EM; Farrand AJ; Polekhina G; Nero TL; Tomlinson S; Parker MW; Tweten RK
J Biol Chem; 2011 Jun; 286(23):20952-62. PubMed ID: 21507937
[TBL] [Abstract][Full Text] [Related]
5. Identification of mutations in rat CD59 that increase the complement regulatory activity.
Hinchliffe SJ; Morgan BP
Biochemistry; 2000 May; 39(19):5831-7. PubMed ID: 10801333
[TBL] [Abstract][Full Text] [Related]
6. Contribution of the N-linked carbohydrate of erythrocyte antigen CD59 to its complement-inhibitory activity.
Ninomiya H; Stewart BH; Rollins SA; Zhao J; Bothwell AL; Sims PJ
J Biol Chem; 1992 Apr; 267(12):8404-10. PubMed ID: 1373727
[TBL] [Abstract][Full Text] [Related]
7. Insights into the human CD59 complement binding interface toward engineering new therapeutics.
Huang Y; Smith CA; Song H; Morgan BP; Abagyan R; Tomlinson S
J Biol Chem; 2005 Oct; 280(40):34073-9. PubMed ID: 16079145
[TBL] [Abstract][Full Text] [Related]
8. Identity of the residues responsible for the species-restricted complement inhibitory function of human CD59.
Zhao XJ; Zhao J; Zhou Q; Sims PJ
J Biol Chem; 1998 Apr; 273(17):10665-71. PubMed ID: 9553129
[TBL] [Abstract][Full Text] [Related]
9. Identity of the segment of human complement C8 recognized by complement regulatory protein CD59.
Lockert DH; Kaufman KM; Chang CP; Hüsler T; Sodetz JM; Sims PJ
J Biol Chem; 1995 Aug; 270(34):19723-8. PubMed ID: 7544344
[TBL] [Abstract][Full Text] [Related]
10. Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59.
Hughes TR; Ross KS; Cowan GJ; Sivasankar B; Harris CL; Mitchell TJ; Morgan BP
Mol Immunol; 2009 Apr; 46(7):1561-7. PubMed ID: 19200600
[TBL] [Abstract][Full Text] [Related]
11. Defining the CD59-C9 binding interaction.
Huang Y; Qiao F; Abagyan R; Hazard S; Tomlinson S
J Biol Chem; 2006 Sep; 281(37):27398-404. PubMed ID: 16844690
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis for a link between complement and the vascular complications of diabetes.
Acosta J; Hettinga J; Flückiger R; Krumrei N; Goldfine A; Angarita L; Halperin J
Proc Natl Acad Sci U S A; 2000 May; 97(10):5450-5. PubMed ID: 10805801
[TBL] [Abstract][Full Text] [Related]
13. Elimination of potential sites of glycosylation fails to abrogate complement regulatory function of cell surface CD59.
Rother RP; Zhao J; Zhou Q; Sims PJ
J Biol Chem; 1996 Sep; 271(39):23842-5. PubMed ID: 8798614
[TBL] [Abstract][Full Text] [Related]
14. Role of a disulfide-bonded peptide loop within human complement C9 in the species-selectivity of complement inhibitor CD59.
Husler T; Lockert DH; Sims PJ
Biochemistry; 1996 Mar; 35(10):3263-9. PubMed ID: 8605162
[TBL] [Abstract][Full Text] [Related]
15. Binding of human and rat CD59 to the terminal complement complexes.
Lehto T; Morgan BP; Meri S
Immunology; 1997 Jan; 90(1):121-8. PubMed ID: 9038722
[TBL] [Abstract][Full Text] [Related]
16. High-resolution structures of bacterially expressed soluble human CD59.
Leath KJ; Johnson S; Roversi P; Hughes TR; Smith RA; Mackenzie L; Morgan BP; Lea SM
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2007 Aug; 63(Pt 8):648-52. PubMed ID: 17671359
[TBL] [Abstract][Full Text] [Related]
17. Identity of a peptide domain of human C9 that is bound by the cell-surface complement inhibitor, CD59.
Chang CP; Hüsler T; Zhao J; Wiedmer T; Sims PJ
J Biol Chem; 1994 Oct; 269(42):26424-30. PubMed ID: 7523406
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for membrane attack complex inhibition by CD59.
Couves EC; Gardner S; Voisin TB; Bickel JK; Stansfeld PJ; Tate EW; Bubeck D
Nat Commun; 2023 Feb; 14(1):890. PubMed ID: 36797260
[TBL] [Abstract][Full Text] [Related]
19. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
Tomlinson S; Whitlow MB; Nussenzweig V
J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complex.
Huang Y; Fedarovich A; Tomlinson S; Davies C
Acta Crystallogr D Biol Crystallogr; 2007 Jun; 63(Pt 6):714-21. PubMed ID: 17505110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
